| Date | Title | Description |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
| 08.01.2025 | Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutationa... | Initial safety and efficacy data from Phase 1 STARt-001 trial showed promising single agent clinical activity in patients with different types of PD-1 resistant tumors including TMB-H colorectal cancer
Global Phase 2 clinical study for invi... |
| 20.12.2024 | Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe | Phase 1 STARt-001 data demonstrated a 25% Overall Response Rate and 50% Disease Control Rate observed at the targeted dose range during the Phase 1 investigation in patients harboring PD-1 resistant tumors with high tumor mutation burden, i... |
| 13.12.2024 | Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 | Results further validate company's novel and proprietary STAR bi-specific antibody platform for selective T cell activation in vivo
CAMBRIDGE, Mass., Dec. 13, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 09.11.2024 | Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting | STARt-001 is the first clinical study to evaluate Marengo’s novel, selective Vβ TCR agonist technology to promote in vivo expansion and reprogramming of tumor-infiltrating lymphocytes (TILs) in patients with advanced cancers
Invikafusp alfa... |
| 30.10.2024 | Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting | Marengo's precision Vβ chain targeted T cell activator technology reinvigorates anti-tumor immune responses in refractory tumor models
Invikafusp alfa is being evaluated as a single-agent in an ongoing Phase 1/2 clinical trial (STARt-001) t... |
| 13.09.2024 | Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers | Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study
The collaboration plans to evaluate the combination of Marengo's first-in-clas... |
| 07.06.2024 | Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T Cell Engagers from Marengo’s Tri-STAR Platform | Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration
Research will focus on using Marengo’s TriSTAR platform to reinvi... |
| 02.04.2024 | Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen | A novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment
Marengo to receive an associated milestone payment and eligible for additional future milestone payments, and tiered royalties
CAMBRIDGE, Mass., April... |
| 01.08.2022 | Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic | Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approach |
| 01.08.2022 | Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic | Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation approach
Ipsen to pay Marengo $45 million upfront with potential for additional miles... |
| 08.11.2021 | Marengo Therapeutics Raises $80M in Funding | Marengo Therapeutics, a Cambridge MA-based company pioneering first-in-class therapeutics that activate the right immune response to promote lifelong protection against cancer, raised $80M in funding.
ATP made the launch investment.
The com... |
| 08.11.2021 | Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform | Differentiated platform built on its groundbreaking discovery of T cell activation via direct antibody targeting of Vβ TCR variants |
| 08.11.2021 | Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform | Differentiated platform built on its groundbreaking discovery of T cell activation via direct antibody targeting of Vβ TCR variants
First-in-class lead molecule slated to enter clinic in 2022
Cambridge, Mass. November 8, 2021 – ATP, a lea... |
| 08.11.2021 | Marengo Therapeutics Launches with $80M |
CAMBRIDGE, MA, Marengo Therapeutics launches with $80 million financing.
>> Click here for more funding data on Marengo Therapeutics
>> To export Marengo Therapeutics funding data to PDF and Excel, click here
ATP announce... |
